Rochester Clinical Research is proud to have worked on the Tirzepatide drug clinical trials over the past few years. We have enrolled over 32 subjects over 2 different studies that have led to the newest findings for this new cutting-edge drug. Study data has been released and shows that it has so far been proven to be effective and safe for patients in reducing their overall BMI over the course of the trial. Rochester Clinical Research continues to conduct more studies with Tirzepatide and other potential weight loss medications.

Per the article on Healio, taking the medication Tirzepatide weekly, has shown an increase in weight loss without even having diabetes. During a 72 week period about participants lost 5% to 20% of their weight compared to placebo. 

A study that was conducted at the American Diabetes Association, showed that in their group of participants, which included 95% prediabetic- that over 1/3 of them ended up losing about 25% of their body weight while on Tirzepatide. 

During the study, researchers were assigning participants with different doses of Tirzepatide such as 5 mg, 10 mg, 15 mg, and the placebo. The study was conducted over a 72 week period and the participants received the dose once a week. During the study researchers found that patients that they gave the 10 mg and 15 mg doses had similar weight loss results. Doctors and researchers say that this is a safe and effective way to lose weight, although it may not work for everyone. 

Tirzepatide is considered a revolutionary new finding when it comes to obesity and weight loss. Rochester Clinical Research wants to work towards getting this drug one step closer to getting approved by the FDA so that it can be available to anyone. We are conducting another study involving Tirzepatide  in the Fall! Call RCR at 585-288-0890 to join our interest list or click the link below.

Weight Loss Study

Rochester Clinical Research is currently seeking male participants who are 18-75 years old for a weight loss study. The study is approximately 64 weeks long and includes 14 visits to the office. You may be compensated for your time and travel to participate in this study.

View Trial Details
Ages 18 – 75
Gender For male patients only
Compensation* TBD
Study Topics Weight Loss

*Compensation for time and travel may be available to those who qualify.

Weight Loss Research Study

Rochester Clinical Research is seeking male participants who are between the ages of 18-70 years old for a weight loss study. The study is approximately 19 weeks long and includes around 11 visits to the office and 2 telephone calls. Compensation will be provided for your trial-related time if you qualify.

View Trial Details
Ages 18 – 70
Gender For male patients only
Compensation* TBD
Study Topics Weight Loss

*Compensation for time and travel may be available to those who qualify.

Cardiac Risk Reduction and Weight Loss Study

Rochester Clinical Research is currently looking for participants who are 18 years or older to participate in a weight loss study. To qualify, participants must have a history of underlying cardiovascular disease, with or without Type II Diabetes. The study is approximately 109 weeks long and will include at least 29 visits but there could be more depending on the data found during the study. Compensation for your time and travel will be provided per visit.

View Trial Details
Ages 18+
Compensation* TBD
Study Topics Weight Loss

*Compensation for time and travel may be available to those who qualify.

Weight Loss Study

Rochester Clinical Research is seeking participants 18 years or older for a weight loss study. The study is approximately 89 weeks long and includes around 14 visits to the office, 10 telephone calls, and 2 additional blood draw-only visits. Compensation will be provided for your trial-related time if you qualify. Please note that this is an extensive research study and you must be 100% committed to participate.

View Trial Details
Ages 18+
Compensation* TBD
Study Topics Weight Loss

*Compensation for time and travel may be available to those who qualify.